UBS’s BioLineRX BLRX Stock Holding History

UBS’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$1K	Sell	1 -16	-94%	-$17.2K	﹤0.01%	10134
2014 Q2	$21K	Buy	17 +12	+240%	+$15K	﹤0.01%	8002
2014 Q1	$7K	Buy	+5	New	+$8.22K	﹤0.01%	9211

Other funds holding BLRX

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCA

Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

NFG

Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

UBS's BLRX Position: Q3 2014 in Review

UBS reduced its BioLineRX (BLRX) stake by 94% in Q3 2014, selling an estimated $17.2K and leaving 1 share worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #10134.

UBS first reported a position in BLRX in Q1 2014 and has held it in 3 quarters since. The position peaked at $21K in Q2 2014. 15 funds tracked by Wall St. Rank hold BLRX as of Q3 2014.

UBS held 1 share of BioLineRX worth $1K as of Q3 2014.
UBS sold 16 BioLineRX shares in Q3 2014, an estimated $17.2K.
BioLineRX made up ﹤0.01% of UBS's portfolio in Q3 2014, its #10134 holding.
UBS first reported a position in BioLineRX in Q1 2014 and has held it in 3 quarters since.
UBS's BioLineRX position peaked at $21K in Q2 2014.
15 funds tracked by Wall St. Rank held BioLineRX as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.